恒指公司：未来聚焦三大发展方向 扩大追踪科技相关指数资产管理规模

Core Insights - The Hang Seng Index achieved its best performance since 2017, with a year-on-year increase of 27.8% as of December 31, 2025, and the assets under management (AUM) linked to the Hang Seng Index series reached approximately $117.7 billion [1] - The Hang Seng Biotechnology Index recorded a year-on-year increase of 64.5%, marking its highest annual growth since its launch in 2025 [1] Group 1: Future Development Directions - The company aims to consolidate its market leadership in the technology and biotechnology sectors, expand the AUM tracking technology-related indices, and continue to develop the biotechnology index while supporting diversified product development [1] - There is a focus on product innovation to explore more applications of artificial intelligence in business, launching products that align with market trends and demands, and developing cross-market indices [1] - The company is committed to advancing its overseas market development to help global investors seize investment opportunities in Hong Kong and mainland China [1] Group 2: Market Trends and New Products - The company noted that the biotechnology sector has gained significant attention from the capital markets, with the biotechnology index outperforming the market and other major indices by over 60% last year [1] - Three structural drivers for the healthcare industry were identified: aging population, rising disposable income, and potential for increased healthcare spending [1] - The company launched the "Hang Seng Dual Technology Index" in January to help investors capture growth opportunities in the technology and biotechnology sectors, with 75% of the index weight allocated to the Hang Seng Technology Index and 25% to the Hang Seng Biotechnology Index [2]